MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'androgen'. Sat, 03 Sep 2011 02:18:43 +0100 http://www.medworm.com/index.php?rid=4151792&cid=t_108496_87_f&fid=39187&url=http%3A%2F%2Fgetbetterhealth.com%2Fwhen-doctors-are-paid-less-unnecessary-prescriptions-drop%2F2010.11.09 Take medical uncertainty. Add financial incentive to treat. Voila! Increased utilization. Now take away financial incentive to treat. Guess what you get? MedPageToday explains, in the case of hormone therapy for prostate cancer: Medicare accomplished what clinical guidelines and evidence-based medicine couldn’t: it reduced unnecessary use of androgen deprivation therapy (ADT) in prostate cancer. Inappropriate use decreased by almost 30% from 2003 to 2005, following enactment of the Medicare Modernization Act, which lowered physician reimbursement for ADT. Appropriate use of ADT did not change during the same time period, according to an article in the Nov. 4 issue of the New England Journal of Medicine. “Our findings suggest that reductions in reimbursement may influence the de... Better Health blogs http://www.medworm.com/rss/comments.php?id=4151792 Tue, 09 Nov 2010 19:00:48 +0100 4151792 http://www.medworm.com/index.php?rid=1873096&cid=t_108496_131_f&fid=34989&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FGeneticsHealth%2F%7E3%2FtQxVqesiHTY%2F The gene for male-pattern baldness (androgen receptor) has traditionally been linked to the X chromosome which means mom passes it on to her sons. Now, two new independent studies published yesterday at the Nature Genetics identified association between hair loss and chromosome 20. A genome-wide association study (GWAS) for male-pattern baldness, or androgenetic alopecia, identified a new association at chromosome 20p11.22, between the PAX1 and FOXA2 genes, and confirmed a previous association with the gene encoding the androgen receptor in the X. Tim Spector and colleagues found that 1 in 7 men carry both the chromosome X and chromosome 20 variants, and that these men have a 7-fold risk of having pattern baldness. Another independent GWAS found overwhelming evidence for five SNPs on chr... Genetics and Health blogs http://www.medworm.com/rss/comments.php?id=1873096 Tue, 14 Oct 2008 03:39:48 +0100 1873096 http://www.medworm.com/index.php?rid=1623065&cid=t_108496_136_f&fid=36051&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FCancerCommentary%2F%7E3%2F335918405%2F In this study of more than 1,400 men, denosumab treatment produced statistically significantly greater increases in bone mineral density (BMD) at the lumbar spine (primary endpoint) and non-vertebral sites compared with placebo at multiple time points. These improvements in BMD were consistent with those seen in other denosumab studies evaluating BMD in women with breast cancer receiving aromatase inhibitor therapy, and in post-menopausal women with low bone mass. During the 36-month evaluation period, men receiving denosumab experienced less than half the incidence of new vertebral fractures (a secondary endpoint) compared with those receiving placebo, a statistically significant finding. Furthermore, in the denosumab arm there were fewer non-vertebral fractures over the 36-month period. ... Cancer Commentary blogs http://www.medworm.com/rss/comments.php?id=1623065 Tue, 15 Jul 2008 09:26:13 +0100 1623065 http://www.medworm.com/index.php?rid=1375200&cid=t_108496_136_f&fid=36051&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FCancerCommentary%2F%7E3%2F271000486%2F Administration of the popular anti-inflammatory drug Celebrex (celecoxib, a nonsteroidal anti-inflammatory drug) in combination with Lipitor (atorvastatin, a cholesterol lowering drug or statin) halts the transition of early prostate cancer to its more aggressive and potentially deadly stage. “Anti-androgen therapy slows the prostate cancer but eventually the cancer becomes androgen-independent, the therapy becomes ineffective and the cancer cells become more aggressive,” said Xi Zheng, assistant research professor at Rutgers, The State University of New Jersey, who conducted the study. “Treatments available for the later stage cancers are not very good,” said Allan Conney, director of Rutgers’ Susan Lehman Cullman Laboratory for Cancer Research, another resea... Cancer Commentary blogs http://www.medworm.com/rss/comments.php?id=1375200 Tue, 15 Apr 2008 22:02:12 +0100 1375200 http://www.medworm.com/index.php?rid=1129518&cid=t_108496_136_f&fid=36051&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FCancerCommentary%2F%7E3%2F210922900%2F This study demonstrates that the benefits of short-term hormonal therapy for men receiving radiation therapy for prostate cancer far outweigh the risks. While four months of hormonal therapy isn’t enough to cause significant side effects, we found that it can delay the development of bone metastasis by as many as eight years, which is very significant. So by taking a little bit of hormonal therapy early, patients may avoid having to take a lot of it later.” The study is published online January 2 in the Journal of Clinical Oncology. Find more details from American Society of Clinical Oncology. Share This (Source: Cancer Commentary) Cancer Commentary blogs http://www.medworm.com/rss/comments.php?id=1129518 Fri, 04 Jan 2008 05:06:23 +0100 1129518 http://www.medworm.com/index.php?rid=1098926&cid=t_108496_136_f&fid=36051&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FCancerCommentary%2F%7E3%2F201532562%2F In this study, 14 extracts were found to be active in inhibiting prostate cancer cells. The findings - active extracts from Ganoderma lucidum were found to be the most effective in inhibiting the function of the androgen receptor and controlling vital development of cancerous cells – is a new, interesting and very promising development in the fight against cancer. Find more details from the University of Haifa. Share This (Source: Cancer Commentary) Cancer Commentary blogs http://www.medworm.com/rss/comments.php?id=1098926 Mon, 17 Dec 2007 08:23:28 +0100 1098926 http://www.medworm.com/index.php?rid=1027424&cid=t_108496_107_f&fid=36585&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FHighlightHealth%2F%7E3%2F184703435%2F This article was published on Highlight HEALTH. (Source: Highlight HEALTH) Highlight HEALTH blogs http://www.medworm.com/rss/comments.php?id=1027424 Wed, 14 Nov 2007 16:35:25 +0100 1027424 http://www.medworm.com/index.php?rid=1005423&cid=t_108496_136_f&fid=36051&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FCancerCommentary%2F%7E3%2F180330117%2F In older women with early stage lung cancer, UCLA’s Jonsson Comprehensive Cancer Center researchers have discovered a novel mechanism to predict their survival. Higher levels of aromatase (an enzyme that naturally makes estrogen from another hormone called androgen) have, for the first time, been linked to more aggressive disease and lower survival rates in women over 65 with Stage 1 or 2 lung cancer. Such findings do not only provide possible need tool in predicting survival but also new target for therapy using aromatase inhibitors. According to the study’s senior author, Lee Goodglick, an associate professor in the UCLA Department of Pathology and Laboratory Medicine and a Jonsson Cancer Center researcher: “All indications suggest that this is a very powerful prognosti... Cancer Commentary blogs http://www.medworm.com/rss/comments.php?id=1005423 Tue, 06 Nov 2007 01:56:30 +0100 1005423 http://www.medworm.com/index.php?rid=1129420&cid=t_108496_136_f&fid=35294&url=http%3A%2F%2Fpsa-rising.com%2Fblog%2Findex.php%2F2007%2F08%2F23%2Fupdate1 When Merv Griffin died on August 12, his family said on his website : Griffin, who turned 82 on July 6th, was recently diagnosed during a routine examination with a recurrence of the prostate cancer that he had overcome more than a decade ago. Its aggressive progression to other organs was unexpected and immediate, according [...] (Source: psa-rising.com/blog) psa-rising.com/blog blogs http://www.medworm.com/rss/comments.php?id=1129420 Thu, 23 Aug 2007 19:37:48 +0100 1129420 http://www.medworm.com/index.php?rid=511180&cid=t_108496_87_f&fid=34865&url=http%3A%2F%2Fwww.thecancerblog.com%2F2007%2F03%2F30%2Ffosamax-prevents-bone-loss-in-prostate-cancer-patients%2F Filed under: Prostate Cancer, Drug, Clinical Trials, ResearchHormonal therapy for prostate cancer can cause many side effects, one being bone loss. The goal of the hormonal therapy is to reduce the levels of the male hormones, called androgens, in the body. The main androgen is testosterone. Androgens can stimulate prostate cells to grow and lowering the levels often makes prostate cancer cells shrink or grow more slowly. The Annals of Internal Medicine published an article that says Fosamax (alendronate) can prevent and even reverse bone loss associated with hormonal treatment for prostate cancer. A trial was conducted that showed after one year bone density had increased among patients treated with Fosamax but had decreased among patients who received a placebo. If you are receiving hor... The Cancer Blog blogs http://www.medworm.com/rss/comments.php?id=511180 Fri, 30 Mar 2007 04:00:00 +0100 511180